{"store":{"baseInfo":{"podcastTitle":"Oncology News Central Peer-Spectives","slug":"peer-spectives","podcastDescription":"Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.","podcastLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/20916722/ONC-Peer-Spectives-small.png","podcastShareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/20916722/ONC-Peer-Spectives-small_1200x628.jpg?s=df83bb7630617686defeee28356fd57e&e=png","podcastUrl":"https://peer-spectives.podbean.com","podcastCanSearched":true,"feedUrl":"https://feed.podbean.com/peer-spectives/feed.xml","theme":"elegant","podcastDeepLink":"https://www.podbean.com/pw/pbblog-94mqu-13f29f2?from=usersite","removePodbeanBranding":"yes","brandingLogo":null,"timeZone":{"timeZoneId":17,"gmtAdjustment":"GMT-04:00","useDaylightTime":1,"value":-4,"text":"(GMT-04:00) Atlantic Time (Canada)","daylightStartTime":"Second Sunday Of March +2 Hours","daylightEndTime":"First Sunday Of November +2 Hours","timezone":"America/Halifax"},"podcastDownloads":null,"totalEpisodes":148,"showComments":true,"iOSAppDownloadLink":null,"customizeCssUrl":null,"androidAppDownloadLink":null,"showPostShare":false,"showLike":false,"author":"Oncololgy News Central","enableEngagementStats":true,"shareEmbedLink":"https://admin5.podbean.com/embed.html?id=pbblog-94mqu-13f29f2-playlist","language":"en","sensitivitySessionExpireTime":3600,"podcastApps":[{"name":"Podbean App","link":"https://www.podbean.com/pw/pbblog-94mqu-13f29f2?from=usersite","image":"https://pbcdn1.podbean.com/fs1/site/images/admin5/podbean-app.png","title":null}],"components":{"base":[{"id":"MainStyle","val":"light"},{"id":"Font","val":"Geometric Humanist"},{"id":"SecondaryFont","val":"Geometric Humanist"},{"id":"PlayerColor","val":"#428200"},{"id":"PlayerStyle","val":"player1"},{"id":"PlayerWave","val":"show"},{"id":"Favicon","val":null},{"id":"CookiesNotice","val":"hide"},{"id":"CookiesNoticeContent","val":"

Cookies Notice

This website uses cookies to improve your experience while you navigate through the website. By using our website you agree to our use of cookies.

"}],"home-header":[{"id":"HomeHeaderTextColor","val":"#000000"},{"id":"HomeHeaderBackgroundColor","val":"#ffffff"}],"page-header":[{"id":"PageHeaderTextColor","val":"#ffffff"},{"id":"PageHeaderBackgroundColor","val":"#868686"}],"episode-list":[{"id":"EpisodeListType","val":"grid"},{"id":"EpisodesPerPage","val":10},{"id":"EpisodeStats","val":"show"}],"navigation":[{"id":"NavigationFontColor","val":"#000000"},{"id":"NavigationBackgroundColor","val":"#e9e9e9"},{"id":"NavigationSearch","val":"show"},{"id":"NavigationLinks","val":[{"id":"Home","type":"Link","value":"/","text":"Home","subitems":[]},{"id":"Subscribe","type":"Link","value":"https://www.podbean.com/site/podcatcher/index/blog/eObXgPHVzixV","text":"Subscribe","subitems":[]},{"id":"Profile","type":"Link","value":"https://www.podbean.com/user-MMo3omCW5FLG","text":"Profile","subitems":[]}]}],"footer":[{"id":"FooterType","val":"Footer2"},{"id":"FooterFontColor","val":"#ffffff"},{"id":"FooterBackgroundColor","val":"#000000"},{"id":"FooterCopyright","val":"HealthCentral, LLC"},{"id":"SocialMediaLinks","val":{"facebook_username":"","twitter_username":"","instagram_username":"","youtube_username":"","linkedin_username":""}}],"customize-container1":[],"customize-container2":[]},"allLinks":[],"mainStylesDefaultSettings":null,"defaultCustomizeComponents":null,"scripts":[],"metas":null,"appConfig":{"package":"com.podbean.app.generic","app_store_id":1484287462,"app_name":"Podbean Biz Podcast App","scheme":"enterprise-podbean-com"},"customizeCss":null,"canEditCss":null,"enableJsCodeInCustomizeContent":false,"enabledIframeCodeInCustomizeContent":true,"sectionMaxCount":10,"enableEditorLink":true,"enableEditCookiesNotice":true,"siteRedirectToFeed":false,"podcatcherRssUrl":null,"showFeed":true,"showTopBar":true,"enableWebSiteLike":false,"organizationName":"HealthCentral","organizationPageLink":"https://www.podbean.com/podcast-network/hcstudioshd898a92"},"backToListUrl":"/","tinymceLoaded":false,"listEpisodes":[],"userLikedEpisodes":[],"userLikeCheckedEpisodes":[],"topBarIframeLoaded":false,"listTotalCount":0,"listTotalPage":0,"listPage":0,"listType":"all","listValue":"","listName":"","pageLoading":false,"apiBaseUrl":"https://peer-spectives.podbean.com","apiCommonParams":{"t":"6866aa44","clientSignature":"d94e8212cee8938affde778caed66a63","u":null,"customizing":null},"apiCommonHeaders":{},"comments":[],"commentsTotalCount":0,"commentsTotalPage":0,"commentsPage":1,"commentEpisodeId":"pb26061008-d3k8b","episode":{"id":"pb26061008","idTag":"d3k8b","title":"Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21","logo":"https://pbcdn1.podbean.com/imglogo/image-logo/20916722/ONC-Peer-Spectives-small_300x300.png","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/20916722/ONC-Peer-Spectives-small_1200x628.jpg?s=df83bb7630617686defeee28356fd57e&e=png","largeLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/20916722/ONC-Peer-Spectives-small.png","previewContent":null,"content":"

Naval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021.

","publishTimestamp":1638459862,"duration":719,"mediaUrl":"https://mcdn.podbean.com/mf/web/vp2gemolp1g1uv7c/secure_obrpodcast_Naval_Daver_Podcast.mp3","mediaType":"audio/mpeg","shareLink":"https://admin5.podbean.com/embed.html?id=pb-d3k8b-18da8d0","likedCount":0,"deepLink":"https://www.podbean.com/ew/pb-d3k8b-18da8d0","transcriptUrl":null,"permalink":"/e/targeted-therapy-and-venclexta-combinations-for-aml-and-a-look-ahead-to-ash-21/","downloadLink":"https://www.podbean.com/media/share/pb-d3k8b-18da8d0?download=1","fallbackResource":null,"fallbackResourceMimetype":null,"downloadCount":1,"status":"publish","hasMoreContent":false,"chaptersUrl":null,"explicit":false},"episodeShareLink":null,"deepLink":"https://www.podbean.com/ew/pb-d3k8b-18da8d0","playlist":{"episodes":[],"current":0,"start":0,"stop":0,"playing":true,"playerLoading":true,"playbackRate":1,"playbackRateIndex":1},"toasts":[],"confirm":null,"customizeEditorFormZIndex":999,"lastRequestTime":null,"validateChangesOnBeforeunload":true,"windowWidth":1000,"VITE_FS1_CDN_URL_PREFIX":"https://pbcdn1.podbean.com/fs1","reloadStats":false,"userIdEncrypted":null,"userProfilePicture":null,"username":null,"isVerified":false,"loadUserInfo":false,"loginUrl":"https://www.podbean.com/site/user/login?return=https%253A%252F%252Fpeer-spectives.podbean.com%252Fe%252Ftargeted-therapy-and-venclexta-combinations-for-aml-and-a-look-ahead-to-ash-21%252F&rts=100098903e60011e2de012786b04cd6fb143fac7","recaptchaV3Loaded":false,"recaptchaV2Loaded":false,"likesLoaded":false,"commentLikeMap":{},"commentOffset":0},"episode":{"id":"pb26061008","idTag":"d3k8b","title":"Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21","logo":"https://pbcdn1.podbean.com/imglogo/image-logo/20916722/ONC-Peer-Spectives-small_300x300.png","shareLogo":"https://d2bwo9zemjwxh5.cloudfront.net/image-logo/20916722/ONC-Peer-Spectives-small_1200x628.jpg?s=df83bb7630617686defeee28356fd57e&e=png","largeLogo":"https://pbcdn1.podbean.com/imglogo/image-logo/20916722/ONC-Peer-Spectives-small.png","previewContent":null,"content":"

Naval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021.